$800 Per Month vs. $40 Per Month: The Hair Loss Medication Math That Nobody’s Talking About

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

But do those impressive-sounding numbers actually translate into visible, meaningful results?

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

But do those impressive-sounding numbers actually translate into visible, meaningful results?

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Recently, headlines have been buzzing about Clascoterone, a new hair loss medication claiming hundreds of percent improvement in hair count.

But do those impressive-sounding numbers actually translate into visible, meaningful results?

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Recently, headlines have been buzzing about Clascoterone, a new hair loss medication claiming hundreds of percent improvement in hair count.

But do those impressive-sounding numbers actually translate into visible, meaningful results?

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.

Recently, headlines have been buzzing about Clascoterone, a new hair loss medication claiming hundreds of percent improvement in hair count.

But do those impressive-sounding numbers actually translate into visible, meaningful results?

Hair restoration surgeons are now taking a closer look at this medication—not through marketing language, but through the lens of mechanism, trial design, and real-world cosmetic change.

What they’re finding might surprise anyone considering this treatment.

Understanding Androgenetic Alopecia and DHT

The most common form of hair loss in both men and women is androgenetic alopecia. This condition is generally considered hormone-driven.

Specifically, dihydrotestosterone (DHT) causes miniaturization of hair follicles. Current treatments focus on preventing progressive hair loss by reducing DHT levels.

Finasteride, for example, blocks testosterone’s conversion to dihydrotestosterone, effectively reducing DHT. However, one main issue with finasteride centers on potential systemic side effects.

Enter Clascoterone: A Different Approach

Clascoterone represents a topically applied androgen receptor inhibitor. More specifically, it competes with DHT for binding to androgen receptors.

The chemical structures of these two compounds are remarkably similar. Clascoterone actually has higher affinity for these receptors than DHT does.

Even with abundant DHT circulating, it cannot bind to androgen receptors as effectively because Clascoterone blocks its way. This is called competitive antagonism.

Clascoterone was approved for acne treatment back in 2020 under the name Winlevi. Its mechanism of action occurs at the receptor level, causing a form of inhibition that prevents DHT from exerting its downstream effects.

The Safety Advantage

One main advantage of Clascoterone is rapid metabolism to its inactive form, cortexolone. This minimizes risk of systemic anti-androgenic side effects.

This could potentially reduce need for orally administered anti-androgenic medications—a significant selling point for patients concerned about systemic effects.

The Clinical Trial Journey

In 2025, Cosmo Pharmaceuticals revealed promising Phase 3 results for Clascoterone 5% solution, showing significant hair growth improvement in androgenetic alopecia. But examining earlier studies reveals important context.

Phase 1 and Phase 2: Mixed Signals

An abstract published in 2019 summarized Phase 1 and Phase 2 studies. Notably, it’s important to consider why this wasn’t published as a full article in medical literature.

The Phase 1 study recruited 18 patients with androgenetic alopecia for a 28-day trial. They applied Clascoterone solution 5% once the first day, then twice daily for 27 days.

Side effects were common: 13 out of 18 patients (72%) experienced at least one treatment-emergent adverse event. All adverse events were considered mild or moderate and resolved before day 28.

These mostly consisted of local skin reactions—erythema, scaling, and dryness. The most likely culprit is propylene glycol, the same chemical in topical minoxidil solution that causes similar reactions.

Phase 2 studies included 70 and 95 patients respectively, testing against other anti-androgens and minoxidil. While Clascoterone showed larger target area hair count changes from baseline versus vehicle, these were not statistically significant at p=0.0971.

Favorable scalp hair growth was reported at 39% for Clascoterone and 36% for minoxidil versus 16% for vehicle. However, the p-value was again not significant at p=0.2213.

For most studies, results must reach p≤0.05 to be statistically significant. Additionally, this research was conducted by Cosmo Pharmaceuticals themselves—introducing considerable bias into these numbers.

Phase 3 Studies: Impressive Numbers, Questions Remain

Two Phase 3 studies called SCALP-1 and SCALP-2 were multi-center, randomized, double-blind, vehicle-controlled trials conducted across the United States and Europe. A total of 1,465 men over age 18 were enrolled.

According to press releases, both trials demonstrated statistically significant improvements compared with vehicle. One study produced a 5.39-fold (539%) relative improvement in target area hair count, while the second showed 1.68-fold (168%) relative improvement.

Cosmo plans to submit to the FDA for possible approval under the name Brazula. As of early 2026, however, no full article disclosing study results has been published.

The Problem With Photographic Evidence

Photographic results released by Cosmo raise questions. In several before-and-after images, outcomes appear related to lighting changes.

Brighter flash in before images creates darker perimeters and lighter central portions. Removing heavy flash in after images naturally makes the overall central portion appear darker.

While some gain from medication may be present, transformations are not tremendous. When compared to outcomes from finasteride and minoxidil seen in clinical practice, results appear less impressive.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown.

This comparison from actual clinical practice demonstrates how powerful finasteride and minoxidil really are. Clascoterone, at least in published images, does not present equivalent or superior benefits.

Statistical Sleight of Hand?

Relative improvement percentages can sound impressive while hiding very small absolute differences. A 539% improvement sounds massive.

But consider this example: if mean target area hair count increased by seven hairs per cm² in the Clascoterone group compared with 1.1 hairs per cm² in vehicle group, this creates an absolute difference of only 5.9 hairs per cm².

That 539% relative improvement translates to just six hairs gained per cm²—unlikely to create visible cosmetic change.

Reports like these can inflate perceived efficacy while obscuring absolute clinical effect: how much change actually appears in before-and-after images.

The Cost Factor Nobody Discusses

When Winlevi’s out-of-pocket costs run $600 to $800 per 60g tube, and DHT-sensitive zones require about 1.5 to 3g of product, that’s approximately 30 applications per tube.

That’s potentially $800 per month on this medication. Insurance companies typically don’t cover hair loss treatments.

Contrast that with proven topical finasteride medications available for about $40 per month. Even if Brazula gains FDA approval, running it against other topical medications becomes essential before spending 20 times the amount on newer medication.

New does not always mean better.

Comparing Mechanisms: Growth Versus Maintenance

Recent medications like PP405 and monounsaturated fatty acids focus on stimulating hair follicle stem cells—a very different mechanism than blocking DHT effects.

Clascoterone is much closer to finasteride and dutasteride in overall mechanism. Perhaps we’re evaluating Clascoterone the wrong way.

Maybe it should be seen more as preventative hair restoration rather than causing significant boosts in hair counts. Clascoterone is being judged through a growth lens when it may be primarily a maintenance drug.

Defense First: The Overlooked Philosophy

One thing lost in discussions about hair loss medications is that success is more than just a single treatment. It’s really about long-term follicle protection.

Focus shifts too heavily toward what can potentially boost hair while forgetting the most important thing: preventing further hair loss.

Finasteride, for example, sometimes grows new hair, but its main mechanism is preventing progressive loss. That same philosophy—defense first—applies outside prescription medications.

This framework emphasizes scalp health, inflammation control, and follicle support to help protect existing hair rather than chasing unrealistic regrowth claims.

The Real Test Lies Ahead

The real test will be whether people with androgenetic alopecia can maintain their hair using topical Clascoterone while avoiding systemic side effects of oral anti-androgen medications.

Whether that holds true remains to be seen. Full published studies, longer-term data, and real-world results will ultimately determine Clascoterone’s place in hair loss treatment.

Until then, proven treatments like finasteride and minoxidil remain first-line options with established track records, accessible pricing, and demonstrated cosmetic outcomes.